期刊
PEDIATRIC BLOOD & CANCER
卷 68, 期 10, 页码 -出版社
WILEY
DOI: 10.1002/pbc.29261
关键词
Castleman disease; idiopathic; JAK inhibition; ruxolitinib; siltuximab
TAFRO is a clinical subtype of idiopathic multicentric Castleman disease characterized by systemic inflammation. Steroids and IL-6 blockade are first-line treatments for iMCD-TAFRO. Some patients with refractory disease present a significant challenge in treatment.
TAFRO (thrombocytopenia, anasarca, fever/elevated C-reactive protein, reticulin myelofibrosis, renal dysfunction, and organomegaly) clinical subtype of idiopathic multicentric Castleman disease (iMCD-TAFRO) is a rare lymphoproliferative disease characterized by systemic inflammation. First-line treatment for iMCD-TAFRO includes steroids and interleukin (IL)-6 blockade. Many patients have refractory disease, which is associated with significant morbidity and mortality, and treatment remains challenging. We present two pediatric cases of iMCD-TAFRO. One patient responded to IL-6 blockade; the other was refractory to siltuximab and chemotherapy, ultimately responding to JAK inhibition with ruxolitinib. This is the first reported pediatric case of refractory iMCD-TAFRO responding to JAK inhibition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据